跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
首页
药物
SARS-CoV-2 therapy
SARS-CoV-2 therapy
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
Antiviral agents for COVID-19 (SARS-CoV-2) combination therapy
申请人: IVASHCHENKO ALEKSANDR VASILYEVICH
优先权: 2020
CN
Targeting SARS-CoV-2 viral-immune interaction for COVID-19 therapy
申请人: UNIV NEW YORK
优先权: 2021
US
2 件公开
Use of iminosugars as prophylactic and therapy against COVID-19 / SARS-CoV-2
申请人: PENN STATE RES FOUND
优先权: 2021
US
Anti-mutation SARS-CoV-2 multi-binding-site IgY, preparation thereof and antibody combination therapy and application
申请人: SHENZHEN YACHEN INTELLIGENT BIOLOGICAL ENG CO LTD
优先权: 2020
CN
Pharmaceutical combination therapy and prevention with aprotinin + nirmatrelvir of SARS-CoV-2 and/or disease associated with this infection, including COVID-19
申请人: ASAVI LLC
优先权: 2022
US
Producing recombinant SARS-CoV-2 spike protein in a pre-fusion state
申请人: ABCLONAL SCIENCE INC
优先权: 2020
CN
US
2 件公开
BROADLY NEUTRALIZING ANTIBODY COMBINATION THERAPIES FOR SARS-COV-2 INFECTION
申请人: VIR BIOTECHNOLOGY INC
优先权: 2021
WO
ANTIBODY COMBINATION THERAPIES FOR SARS-COV-2 INFECTION
申请人: VIR BIOTECHNOLOGY INC
优先权: 2021
WO
药物
反馈